Skip to main content
SpringerLink
Log in

Atrial fibrillation ablation: is common practice far from guidelines’ world? The Italian experience from a national survey

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Purpose

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. Catheter ablation has become an important treatment modality for patients with symptomatic drug-refractory AF. We report data regarding the AF ablation approaches and modalities in the Italian “real world.”

Methods

The survey was set-up to collect data on ablation procedure across Italy. All centers performing AF ablation were invited, regardless of the number of annual procedures, to complete a questionnaire regarding their ablation approaches. All centers reported data regarding procedures performed during the year 2017.

Results

A total of 3260 procedures were reported from 49 participating hospitals. Most of Italian regions were included in the study. The majority of the centers performed “Always” pulmonary vein isolation (PVI) in paroxysmal and persistent AF catheter ablation, while adjunctive lesions in persistent AF ablation were planned in most of them but not all, and 16% never performed lesions other than PVI. During ablation procedure, vitamin k inhibitors were uninterrupted in 55% of centers, while direct oral anticoagulant in 44% of centers was used uninterruptedly. No relationship was observed between patient data and the number of procedures performed at each center.

Conclusions

This survey suggests that the adherence of Italian centers to the most recent European Society of Cardiology guidelines for AF ablation is reasonably high.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J; 37:2893-2962.

  2. Themistoclakis S, Tritto M, Bertaglia E, Berto P, Bongiorni MG, Catanzariti D, et al. Catheter ablation of atrial fibrillation: Health Technology Assessment Report from the Italian Association of Arrhythmology and Cardiac Pacing (AIAC). G Ital Cardiol (Rome). 2011;12:726–76.

    Google Scholar 

  3. Schmidt B, Brugada J, Arbelo E, Laroche C, Bayramova S, Bertini M, et al. Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry. Europace. 2020;22:558–66.

    Article  Google Scholar 

  4. Tilz RR, Dagres N, Arbelo E, Blomstrom-Lundqvist C, Crijns H, Kirchhof P, et al. Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. Europace. 2020;22:250–8.

    Article  Google Scholar 

  5. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace. 2018;20:157–208.

    Article  Google Scholar 

  6. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, et al. ‘Real-world’ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace. 2016;18:648–57.

    PubMed  Google Scholar 

  7. Nagao T, Suzuki H, Matsunaga S, Nishikawa Y, Harada K, Mamiya K, et al. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace. 2019;21:590–7.

    Article  Google Scholar 

  8. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez ES, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129:2638–44.

    Article  Google Scholar 

  9. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.

    Article  CAS  Google Scholar 

  10. Di Monaco A, Guida P, Vitulano N, Quadrini F, Troisi F, Langialonga T, et al. Catheter ablation of atrial fibrillation with uninterrupted anticoagulation: a meta-analysis of six randomized controlled trials. J Cardiovasc Med (Hagerstown). 2020;21:483–90.

    Article  Google Scholar 

  11. Kuwahara T, Abe M, Yamaki M, Fujieda H, Abe Y, Hashimoto K, et al. Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol. 2016;27:549–54.

    Article  Google Scholar 

  12. Müller P, Halbfass P, Szöllösi A, Dietrich JW, Fochler F, Nentwich K, et al. Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2016;46:203–11.

    Article  Google Scholar 

  13. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627–36.

    Article  CAS  Google Scholar 

  14. Calkins H, Willems S, Verma A, Schilling R, Hohnloser SH, Okumura K, et al. Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. Europace. 2019;21:879–85.

    Article  Google Scholar 

  15. Heidbuchel H, Dagres N, Antz M, Kuck KH, Lazure P, Murray S, et al. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. Europace. 2018;20:1919–28.

    Article  Google Scholar 

  16. Dan GA, Iliodromitis K, Scherr D, Marin F, Lenarczyk R, Estner HL, et al. Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. Europace. 2018;20:1382–7.

    Article  Google Scholar 

  17. Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al. Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. Eur Heart J. 2016;37:610–8.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Gemma Pelargonio and Antonio Di Monaco contributed equally to this work.

Authors and Affiliations

  1. Dipartimento di Scienze Cardiovascolari Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

    Gemma Pelargonio & Maria Lucia Narducci

  2. Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Roma, Italy

    Gemma Pelargonio

  3. Dipartimento di Cardiologia. Ospedale Generale Regionale “F. Miulli”, Acquaviva delle Fonti (Bari), Italy

    Antonio Di Monaco, Pietro Guida & Massimo Grimaldi

  4. Dipartimento di Cardiologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Foggia, Foggia, Italy

    Pier Luigi Pellegrino

  5. Unità Operativa di Aritmologia, Ospedale San Raffaele di Milano, Segrate, Italy

    Pasquale Vergara

  6. Unità operativa di Elettrofisiolgia ed Elettrostimolazione, Humanitas Mater Domini, Castellanza (Varese), Italy

    Massimo Tritto

Authors
  1. Gemma Pelargonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Di Monaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pietro Guida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pier Luigi Pellegrino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pasquale Vergara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Massimo Grimaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Lucia Narducci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Massimo Tritto
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

AIAC Task Force AF Ablation

Corresponding author

Correspondence to Antonio Di Monaco.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

AIAC membership: all the authors are AIAC members. Pelargonio and Tritto are chiefs of AIAC Task Force AF Ablation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pelargonio, G., Di Monaco, A., Guida, P. et al. Atrial fibrillation ablation: is common practice far from guidelines’ world? The Italian experience from a national survey. J Interv Card Electrophysiol 63, 125–132 (2022). https://doi.org/10.1007/s10840-021-00955-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-021-00955-7

Keywords

Search

Navigation